There is one open-label intravenous safety pilot in two healthy adults, who received single doses of 10 mg and 20 mg with no comparator, no blinding, and short-term observation limited to vital signs, self reported symptoms and labs across two days [4]
Models for nephrotoxicity screening Conventional in vitro models Until recently, researchers were left with only two options: in vitro cultures of primary human cells or the use of animal models, both having limitations
Its potential is immense, but only if it's prepared correctly
The FDA scientists are set to present their conclusions next month at an FDA advisory committee meeting that will assess whether to allow compounding pharmacies to produce seven different peptides
Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder
Evaluation and management of residual cardiovascular risk in patients with diabetes